SCRS Announces Partnership with TrialScout
The Society for Clinical Research Sites (SCRS) has announced the addition of a patient engagement and retention platform to its member benefit package. Offered in partnership with TrialScout, the platform will help SCRS member sites build their brand with patients and sponsors, providing access to patient experience ratings and reviews and monthly analytics to optimize site operations.
Available to qualifying member sites domestically and abroad as a part of the SCRS Member Affinity Program (MAP), member sites now have access to the following services:
- Stand out from other sites by creating a premium profile;
- Engage patients on the ratings and reviews platform in clinical trials;
- Monthly analytics report provided on patient experience data to identify barriers to participation and reduce dropout.
“TrialScout’s patient experience platform is focused on empowering site success and recognizing site excellence,” said CEO Dr. Irfan Khan. “SCRS member sites are the very sites we feel are best suited to benefit from TrialScout’s ability to enhance the patient experience in clinical research.”
“Through TrialScout, SCRS member sites will be able to gain a deeper understanding into how they are perceived by their communities and patients, and will have access to a new means to showcase their capabilities with the sponsors and CROs they work with,” said SCRS VP of global engagement, Dan Milam. “We are thrilled to add TrialScout’s patient engagement and retention platform as our second MAP offering as an additional way to enhance site sustainability.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
